Abstract
The increased use of prostate-specific membrane antigen (PSMA) based PET imaging for prostate cancer (Pca) detection has revolutionized the clinical management of Pca, with higher diagnostic sensitivity for extraprostatic disease and increasing clinical utility across different stages of the disease. The integration of PSMA PET imaging into clinical guidelines and consensus documents reflects its growing importance in the personalized management of Pca. This review of recent literature highlights the rapid evolution of PSMA PET into the mainstream of staging and restaging and the decreasing reliance on conventional imaging modalities. This comprehensive review serves as a resource for clinicians and researchers involved in the domains of Pca diagnosis and management.